Adalimumab Injection + Placebo
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frozen Shoulder
Conditions
Frozen Shoulder
Trial Timeline
Jul 21, 2022 → Jun 12, 2023
NCT ID
NCT05299242About Adalimumab Injection + Placebo
Adalimumab Injection + Placebo is a phase 2/3 stage product being developed by 180 Life Sciences for Frozen Shoulder. The current trial status is completed. This product is registered under clinical trial identifier NCT05299242. Target conditions include Frozen Shoulder.
Hype Score Breakdown
Clinical
15
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05299242 | Phase 2/3 | Completed |